



(51) International Patent Classification:

A61K 31/192 (2006.01) A61P 3/06 (2006.01)
A61K 31/4468 (2006.01) A61K 39/395 (2006.01)
A61K 31/7088 (2006.01)

(21) International Application Number:

PCT/US2014/065742

(22) International Filing Date:

14 November 2014 (14.11.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/906,837	20 November 2013 (20.11.2013)	US
61/942,438	20 February 2014 (20.02.2014)	US
61/942,941	21 February 2014 (21.02.2014)	US
61/974,816	3 April 2014 (03.04.2014)	US
61/974,785	3 April 2014 (03.04.2014)	US
61/974,725	3 April 2014 (03.04.2014)	US

(71) Applicant: CYMABAY THERAPEUTICS, INC.

[US/US]; 7999 Gateway Blvd., Suite 130, Newark, CA 94560 (US).

(72) Inventors: MARTIN, Robert, L.; 7999 Gateway Blvd.,

Suite 130, Newark, CA 94560 (US). MCWHERTER, Charles, A.; 7999 Gateway Blvd., Suite 130, Newark, CA 94560 (US). O'MARA, Patrick, J.; 7999 Gateway Blvd., Suite 130, Newark, CA 94560 (US).

(74) Agents: NGUYEN, Sam, L. et al.; Hamilton, DeSanctis & Cha, LLP, 3239 El Camino Real, Ste. 220, Palo Alto, CA 94306 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

(57) Abstract: (R)-2-(4-((2-Ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)- acetic acid or a salt thereof; optionally in combination with an MTP inhibitor, an apoB- 100 synthesis inhibitor, or a PCSK9 inhibitor; is useful in the treatment of homozygous familial hypercholesterolemia.

